All In Biotech

Drug Trial Radar · NCT07029971

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis

A Phase 1a/b Clinical Trial To Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of BB-TL1A-VIAL-HLE in Healthy Adult Volunteers and in Patients With Moderate-To-Severe Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

Jun 23, 2025

Primary completion

Dec 23, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Vial Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if BB-TL1A-VIAL-HLE is safe in healthy adults and is safe and effective in treating adults with moderate-to-severe ulcerative colitis. The main questions it aims to answer are: Is the intervention safe in healthy adults and in adults with moderate-to-severe ulcerative colitis? Is the intervention effective in treating adults with moderate-to-severe ulcerative colitis? Researchers will compare the Phase 1b arm to a historical treatment arm to estimate the drug's effect size and see if the study drug is at least as effective as a relevant benchmark. Participants will: * Attend the clinical research site several times over the course of \~1 year * Have blood and urine samples taken * Undergo physical examinations * Receive one injection of the study drug

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • BB-TL1A-VIAL-HLEBiological

    Anti-TL1A monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting or intolerable treatment related adverse eventsTime frame: From enrollment to the end of the follow up period at Day 355
  2. Incidence, severity and causal relationship of treatment emergent AEs (TEAEs) and withdrawals due to TEAEsTime frame: From enrollment to the end of the follow up period at Day 355
  3. Incidence and magnitude of abnormal laboratory findingsTime frame: From enrollment to the end of the follow up period at Day 355
  4. Abnormal and clinically relevant changes in vital signs, blood pressure and electrocardiogram parametersTime frame: From enrollment to the end of the follow up period at Day 355
  5. Percentage of participants who achieve endoscopic improvement at 12 weeks post-dose (Ph-1b)Time frame: From enrollment to end of induction period at 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dymocks Building, WellShare Site

    Sydney, New South Wales, Australia

  • Arcadia Pittwater Private Hospital (Operated by Battery Bio)

    Warriewood, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.